Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity
Public ClinicalTrials.gov record NCT07776678. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Redefining Evaluation of Adiposity and Leanness: Broadening Objective Diagnostics for Obesity (REAL-BODY)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate body composition across a variety of medical, professional, and commercial devices, including: bioelectrical impedance analysis (BIA) devices, 3-dimensional optical imaging (3DO), manual anthropometry measurements, dual-energy X-ray absorptiometry (DXA), magnetic resonance imaging (MRI), and blood tests. The secondary study purpose is to compare body composition measurements from BIA devices, 3DO, and manual anthropometry measurements within a 1-week period for a subset of the study population. The study plans to enroll 300 healthy (having no life-threatening conditions or diseases; male and female) participants, 18 years of age or older.
Study identification
- NCT ID
- NCT07776678
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
Not listed
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 28, 2026
- Primary completion
- Nov 29, 2026
- Completion
- Mar 29, 2027
- Last update posted
- Aug 19, 2026
2026 – 2027
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Exponent Phoenix | Phoenix | Arizona | 85027 | Recruiting |
| Exponent Menlo Park | Menlo Park | California | 94025 | Not yet recruiting |
| Exponent Boston | Boston | Massachusetts | 01760 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Obesity & Overweight trials
Other public records listing Obesity & Overweight. Sorted by last update posted; newest first. Not a recommendation.
- NCT07787533: Digital Resistance Training for Midlife Women Using GLP-1 Not yet recruiting
- NCT07778524: Alpelisib Challenge Test (ACT) Not yet recruiting
- NCT07509502: Optimizing Lifestyles Through Increased Vegetable-rich Eating Pilot Study Active, not recruiting
- NCT07747805: GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD Not yet recruiting
- NCT07743567: Gestational Response, Outcomes, and Weight After GLP-1 Use Recruiting
- NCT07446907: Optimizing Adaptive Intensive Behavioral Therapy for Obesity During the Transition to Older Adulthood Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07776678, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2026 · Synced Aug 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07776678 live on ClinicalTrials.gov.